Comparison of B-Cell Lupus and Lymphoma Using a Novel Immune Imbalance Transcriptomics Algorithm Reveals Potential
Naomi Rapier-Sharman1, Sehi Kim1, Madelyn Mudrow1
1Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA.
Genes
|September 28, 2024
Summary
Systemic lupus erythematosus (lupus) and B-cell lymphoma share molecular mechanisms, identified by a novel Immune Imbalance Transcriptomics (IIT) algorithm. This research uncovers shared and distinct gene targets for potential new lupus and lymphoma therapies.
Area of Science:
- Immunology
- Genomics
- Computational Biology
Background:
- Systemic lupus erythematosus (lupus) and B-cell lymphoma (lymphoma) co-occur more often than expected.
- Both diseases heavily involve B cells in their pathology, suggesting shared molecular mechanisms.
Purpose of the Study:
- To identify shared and contrasting molecular mechanisms between lupus and lymphoma.
- To discover potential therapeutic targets by analyzing B cell gene expression data.
Main Methods:
- Implementation of a novel Immune Imbalance Transcriptomics (IIT) algorithm.
- Application of IIT to RNA-sequencing data from lupus, lymphoma, and healthy B cells.
Main Results:
- Identified 7143 significantly dysregulated genes common to both lupus and lymphoma.
- 5137 genes showed significant immune imbalance according to IIT, including pathways like "Neutrophil Degranulation" and "Adaptive Immune System".
- Discovered 344 IIT gene products as known drug targets, with 48 known and 296 novel targets for lupus, and 151 known and 193 novel targets for lymphoma.
Conclusions:
- The IIT algorithm effectively identifies biologically relevant immune and inflammation-related genes.
- The identified shared and contrasting gene mechanisms provide a foundation for developing novel immune-related therapies for lupus and lymphoma.
